Extended dual antithrombotic therapy in patients with chronic coronary syndrome — which agent should be added to aspirin?

Extended dual antithrombotic therapy in patients with chronic coronary syndrome — which agent should be added to aspirin?

According to the 2024ESC Guidelines for the management of chronic coronary syndromes dual antithrombotic treatment comprising aspirin and a second antithrombotic drug for extended long-term prevention should be considered in patients at increased ischemic risk without high bleeding risk. However, no...

Full description

Saved in:
Bibliographic Details
Main Authors: Jacek Kubica, Piotr Adamski, Katarzyna Buszko, Piotr Buszman, Nader Elmasri, Tomasz Fabiszak, Jakub Foryś, Robert Gajda, Mariusz Gąsior, Robert Gil, Paweł Grzelakowski, Tomasz Hajdukiewicz, Miłosz Jaguszewski, Adam Kern, Wacław Kochmann, Jacek Konarski, Aldona Kubica, Tobiasz Kudla, Wiktor Kuliczkowski, Aleksandra Kusińska-Czyczyło, Ewa Laskowska, Przemysław Magielski, Piotr Michalski, Krzysztof Milewski, Natalia Mrzywka, Piotr Niezgoda, Małgorzata Ostrowska, Maciej Piasecki, Przemysław Podhajski, Janusz Prokopczuk, Jakub Ratajczak, Alicja Rzepka-Cholasińska, Grzegorz Skonieczny, Giuseppe Specchia, Łukasz Szarpak, Paweł Szymański, Małgorzata Topolska, Julia M. Umińska, Marcin Ziółkowski, Aleksander Żurakowski, Eliano Pio Navarese
Format: Article
Language:English
Published: Via Medica 2025-06-01
Series:Cardiology Journal
Subjects:
extended antithrombotic therapy
chronic coronary syndrome
rivaroxaban
ticagrelor
clopidogrel
prasugrel
Online Access:https://journals.viamedica.pl/cardiology_journal/article/view/104821
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://journals.viamedica.pl/cardiology_journal/article/view/104821

Similar Items